Accordingly, blockade of BAFF and APRIL activity via atacicept (TACI-Ig, a fusion protein containing the ligand-binding domain of the receptor TACI and the Fc portion of hIgG1) and BCMA decoy receptor (sBCMA-Fc), can be sufficient to reduce tumor burden in mouse models of MM [31,32]. The gene discussed is TNFRSF13B; the disease is neoplasm.